The human (IL-8) ELISA test for human interleukin 8 quantifies human LIL-8 in serum, plasma, cell culture supernatants, amniotic fluid or other human body fluids. The test will recognize the...
The human (IL-8) ELISA test for human interleukin 8 quantifies human LIL-8 in serum, plasma, cell culture supernatants, amniotic fluid or other human body fluids. The test will recognize only natural and recombinant IL-8 Hu. Method Principle The ELISA solid phase sandwich test of human IL-8 (immuno-enzymatic test) is designed to measure the amount of the target bound between a pair of paired antibodies. A target-specific antibody was pre-vested in the wells of the supplied microplate. Samples or controls are then added to these wells and are linked to immobilized antibodies (capture). The sandwich is formed by binding the second antibody (detector) to the target on a different epitope from the capture antibody. An antibody conjugated with the enzyme binds the formed sandwich. After incubation and washing steps to remove the microplate from the non-bonded substances, a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this coloured product is directly proportional to the concentration of TP (p) present in the original sample. Rigorous validation Each batch manufactured from this ELISA kit is tested for quality for criteria such as sensitivity, specificity, accuracy and batch-to-batch consistency. See the product manual for more information on validation.
IL-8 (Interleukine-8) is an amino acid 72 pro-inflammatory CXC chemokine called CXCL8, secreted by endothelial cells and monocytes, which acts as an important chemotactic for neutrophils as well as T cells and basophiles. Il-8, isolated for the first time from the cells of the osteosarcoma, contains the ELR pattern (the sequence of amino acids end to end N-terminal Glu-Leu-Arg) and signals via the CXCR1 and CXCR2 receptors. Cancer studies have shown a role for IL-8 in angiogenesis and tumour growth. The previous nomenclature for the IL-8 includes neutrophil 1 (NAP-1), granulocyte 1 (GCP-1) chemotactic protein, neutrophil monocyte-derived activator peptide (MONAP) and protein 3-10 C.
Sensitivity
Sensitivity of dosage: 1.3 pg/ml.
Measurement range
Dose range: 15.6-1.000 pg/ml.
Duration of dosing
Total duration of dosing: 3 h 10 min.
Reproducibility
Coefficient of variation intra-dose 8.1%, inter-dose 10.8%.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 15591547 |
| Specifications |
| Accession number | P10145 |
| Dose range | 15.6-1.000 pg/ml |
| Sensitivity of the dosage | 1.3 pg/ml |
| Conjugate | Biotin |
| Product type | Kit ELISA |
| Type of sample | Amniotic liquid, Serum, Surnatant, Supernatant |
| Target species | Human |
| For use with (application) | ELISA |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 3576 |
| Gene symbol(s) | GCP-1,GCP1,IL8,LECT,LUCT,LYNAP,MDNCF,MONAP,NAF,NAP-1,NAP1 |
| Coefficient of inter-dose variation | 10.8% |
| Coefficient of intra-dose variation | 8.1% |
| Contents of kits | Adhesive plate covers, Biotinylated detection antibody, 10x lysis pad, 10x lysis pad, 96-well pre-coated microplate, Stop solution, Sample diluent, Sample diluent, Wash buffer concentrate, Wash buffer concentrate, Substrate solution |
| Marker or dye | HRP |
| Quantity | 128 Tests |
| Regulatory status | RUO |
| Synonym | Protein 3-10C, CXCL8, NAP-1, GCP-1 |
| Target | Human |
| Test time | 20 min |
| Physical characteristics |
| Volume of sample | Amniotic liquid, 50 μl; plasma, 50 μl; serum, 50 μl; supernatant, 50 μl |
| Storage and shipping |
| Storage conditions | -20°C |
| Total duration of dosing | 3 h 10 min |
Origin and customs
| Manufacturer ref. | BMS204-3INST |
|---|
| Country of origin | Autriche |
|---|
| HS customs code | 3002 15 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.